High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Stock Market Today: The Dow Jones index falls, but tech futures rally Thursday as Nvidia, Salesforce and CrowdStrike surge on earnings.
Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.
If approved in EoE, Tezspire will notch another indication onto its belt – adding to its legacy defined by approvals in asthma and CRSwNP.
Amgen (NasdaqGS:AMGN) has elected to terminate its research collaboration and license agreement with TScan Therapeutics focused on Crohn's disease target discovery. The decision ends Amgen's exclusive effort with TScan to identify and develop T-cell antigen targets for Crohn's disease. This change may affect Amgen's research pipeline in inflammatory bowel disease and influence its future approach to biotech partnerships. For broader context on the sector, consider exploring other...
Amgen has had an impressive run over the past six months as its shares have beaten the S&P 500 by 5.7%. The stock now trades at $441.95, marking a 16.5% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Three catalysts, one reshuffling, and a Fed that refuses to move
Amgen, Thermo Fisher and PepsiCo headline today's research, with growth drivers, strategic moves and key risks in focus.
AMGN's strong growth drivers and promising pipeline support long-term growth, but patent losses, pricing pressure and valuation warrant caution.
AMGN, FCFS and DK delivered strong gains, highlighting Zacks research successes across several model portfolios.
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.
Suddenly the Nasdaq couldn’t hold onto early gains, and you can probably guess which stocks are to blame. The Nasdaq Composite was hovering around breakeven after a wave of selling hit chips and AI infrastructure stocks. The S&P 500 was still up 0.3%.
Analyst reaction to Amgen’s latest quarter Amgen (AMGN) is back in focus after Argus raised its price target to $460 from $375 while maintaining a Buy rating, following second quarter results and reported progress across the company’s drug portfolio. See our latest analysis for Amgen. Beyond the latest quarter, Amgen’s recent news sits against strong momentum in the stock, with a 30 day share price return of 18.49% and a 1 year total shareholder return of 51.76%. This points to building...
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
One large-cap drugmaker has quietly lapped its peers in 2026 without a single obesity drug in its lineup, while the companies chasing the hottest trend in pharma are fighting for second place and last.
Both Amgen and Repligen saw price target hikes after better-than-expected Q2 results and potential gains from Moderna’s successful Phase 3 trial for melanoma therapy, respectively.
Investors rotated toward profitable drugmakers while personalized cancer-vaccine results energized biotechnology stocks.
Ben Zercher is senior analyst of biotech and pharma at PitchBook Obesity drugs offered the holy grail of drug development: a massive market, biology that works, and a proven blueprint paved by blockbuster GLP-1s. But the gold rush led by Big Pharma and investors has ended. The market is punishing developers whose drugs fail to stand out, and pipelines are being trimmed. Pfizer just axed another program from its massive Metsera deal, while peers like Amgen have begun trimming their own early-stag
Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.
President Trump is asking cybersecurity and tech companies to take on a potentially dangerous new role attacking foreign cybercriminals, but the plan offers few incentives to balance the risks. Genetic testing lab Baylor Genetics disclosed a cyber incident where a hacker had access to certain internal systems between June 11 and June 17. An unspecified number of patients had their medical testing and lab results compromised while current and former employees had their Social Security numbers and financial account data exposed, Baylor said.
By Karen Roman Fulcrum Therapeutics, Inc. (Nasdaq: FULC) said it is merging with Slate Medicines, Inc. to advance next-generation therapeutics to treat migraine and other headache disorders, with the combining company operating as Slate Medicines, Inc. and trading on Nasdaq under the ticker “SLTE.” Slate reported it secured an oversubscribed concurrent private placement of $245 […] The post Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies appeared first on Exec
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
